You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

interleukin-15 (IL-15)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Cancer, Pancreas Cancer, Ovarian Cancer Trial in Edegem (IL15-transpresenting WT1-targeted Dendritic Cell Vaccine)

Not yet recruiting
  • Esophageal Cancer
  • +3 more
  • IL15-transpresenting WT1-targeted Dendritic Cell Vaccine
  • Edegem, Belgium
    Antwerp University Hospital
Jul 19, 2023

Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides Trial run by the NCI (Recombinant human Interleukin-15

Completed
Has Results
  • Adult T-Cell Lymphoma/Leukemia
  • +2 more
  • Recombinant human Interleukin-15 (rhIL-15)
  • Mogamulizumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 9, 2022

HIV/AIDS Trial in Bangkok (N-803)

Recruiting
  • HIV/AIDS
  • Bangkok, Thailand
    Thai Red Cross AIDS Research Centre
Oct 4, 2021

Active Non Segmental Vitiligo Trial in Cairo (Narrow band ultraviolet B)

Completed
  • Active Non Segmental Vitiligo
  • Narrow band ultraviolet B
  • Cairo, Helwan, Egypt
    Nourhan Emad
Aug 8, 2022

Leukemia, Lymphocytic, Chronic Trial run by the NCI (rhIL-15, Obinutuzumab)

Terminated
Has Results
  • Leukemia
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Mar 11, 2022

Clear-Cell Renal Carcinoma Trial run by the NCI (rhIL-15, Avelumab)

Terminated
Has Results
  • Clear-Cell Renal Carcinoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 27, 2022

T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL) Trial run by the NCI (IL-15 plus,

Completed
Has Results
  • T-Cell Lymphoma Relapsed
  • +4 more
  • IL-15 plus
  • alemtuzumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 27, 2022

Lynch Syndrome Trial in Puerto Rico, United States (procedure, drug, other, biological)

Not yet recruiting
  • Lynch Syndrome
  • Biopsy
  • +5 more
  • Phoenix, Arizona
  • +13 more
Sep 16, 2022

Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in United States (NKTR-255 at 1.5 µg/kg, NKTR-255

Recruiting
  • Non-Hodgkin Lymphoma
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • NKTR-255 at 1.5 µg/kg
  • +3 more
  • La Jolla, California
  • +26 more
Jan 10, 2023

Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

Not yet recruiting
  • Myeloma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Neuroblastoma, Osteosarcoma Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Neuroblastoma
  • Osteosarcoma
  • iC9.GD2.CAR.IL-15 T-cells
  • +2 more
  • Atlanta, Georgia
  • +1 more
Jan 4, 2023

Metastatic Colorectal Cancer Trial run by the National Cancer Institute (NCI) (Retifanlimab, Therapeutic CEA, Brachyury and MUC1

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 4, 2023

Vitiligo Trial (Interleukin-15 and Interleukin-22)

Not yet recruiting
  • Vitiligo
  • Interleukin-15 and Interleukin-22
  • (no location specified)
Nov 14, 2021

Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Neuroblastoma
  • GINAKIT Cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Jan 18, 2023

Liver Cell Carcinoma Trial in Houston (CATCH T cells, Cytoxan, Fludara)

Recruiting
  • Liver Cell Carcinoma
  • +7 more
  • CATCH T cells
  • +2 more
  • Houston, Texas
    Houston Methodist Hospital
Dec 19, 2022

Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T Infusion)

Not yet recruiting
  • Lung Cancer
  • +2 more
  • iC9.GD2.CAR.IL-15 T Infusion
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Nov 16, 2022

NonHodgkin's Lymphoma Refractory Trial in El Segundo (N803, CD19t-haNK suspension, Cyclophosphamide)

Not yet recruiting
  • NonHodgkin's Lymphoma Refractory
  • El Segundo, California
    CSSIFM
Nov 9, 2022

Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma Trial in Houston (CAR.70/IL15-transduced CB-derived

Not yet recruiting
  • Advanced Renal Cell Carcinoma
  • +2 more
  • CAR.70/IL15-transduced CB-derived NK cells
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Boston (Interleukin-15

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Interleukin-15 Superagonist (N-803)
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 2, 2022

Cancer, Tumor, Solid, Advanced Solid Tumor Trial in Brussels, Barcelona, Madrid (JK08)

Recruiting
  • Cancer
  • +6 more
  • Brussels, Belgium
  • +3 more
Jan 30, 2023

HIV Infection Trial in United States (N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074)

Recruiting
  • HIV Infection
  • N-803 (IL-15 Superagonist)
  • +2 more
  • Los Angeles, California
  • +11 more
Sep 22, 2022

Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Minneapolis (N-803)

Completed
  • Acute Myelogenous Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Jan 4, 2023

Hematological Malignancy Trial in Houston (Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells)

Not yet recruiting
  • Hematological Malignancy
  • Fludarabine Phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)

Not yet recruiting
  • Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

High-risk MDS, Acute Myelogenous Leukemia, Systemic Mastocytosis Trial in Minneapolis, Madison (GTB-3550 TriKE® Phase I,

Terminated
  • High-risk Myelodysplastic Syndromes
  • +3 more
  • GTB-3550 TriKE® Phase I
  • GTB-3550 TriKE® Phase II
  • Minneapolis, Minnesota
  • +1 more
Mar 21, 2022